To evaluate the efficacy and safety of edoxaban in the prevention of tumor catheter-related thrombosis (CVC/PICC) in high-risk patients
Age≥18.
Cancer patients with a catheter-related thrombus risk prediction model score ≥ 19.6.
ECOG score≤2.
Expected survival period over 6 months.
Unknown location of the primary tumor.
Allergy to the active ingredient of edoxaban tablets or other excipients.
There is clinically significant active bleeding.
Platelet <50×109/L.
Parallel
Edoxaban
DrugEdoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
The incidence of catheter-related thrombosis during catheter
The incidence of bleeding caused by edoxaban
The incidence of bleeding caused by edoxaban including major bleeding, clinically relevant non-major bleeding and minor bleeding. The criteria is shown in Appendix 3.
The mortality rate caused by catheter-related thrombosis
The time of non thrombotic events
The incidence of venous thrombosis
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
